TrialBlood2022

Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial.

Tait D Shanafelt et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.